“Moderna obtained technical know-how relating to GSK biologicals’s mRNA vaccine platform technology by hiring several former Novartis and GSK employees with first-hand knowledge of the Mandl team’s ...

Moderna to defend against GSK's claims, spokesperson says GSK seeks unspecified monetary damages from Moderna A spokesperson for Massachusetts-based Moderna said the company was aware of the ...

(Reuters) -British drugmaker GlaxoSmithKline sued Moderna in U.S. federal court in Delaware on Tuesday, accusing it of violating GSK patent rights in messenger RNA technology with its blockbuster ...

GSK’s blockbuster hopes for depemokimab remain on track after the investigational long-acting asthma treatment has also been shown to reduce nasal polyps in a pair of phase 3 trials. The ANCHOR ...

According to GSK, as much as 4% of the general population is affected by the condition, which can be associated with asthma and allergic rhinitis. Dupixent, which has become one of the pharmaceutical ...

GSK to pay $2.2 billion to settle 93% of Zantac-related lawsuits. GSK targets £38 billion in sales by 2031, but market estimates fall short at £35.7 billion These cases account for 93% of the ...

The UK based drug firm GSK has agreed to pay up to $2.2bn (£1.7bn; €2bn) to settle claims that the heartburn drug ranitidine (previously marketed in the US as Zantac) caused cancer. The deal, ...

Shares in pharmaceutical company GlaxoSmithKline (GSK) surged more than 6% after the company revealed it had reached a settlement of up to $2.2bn (€2.01bn) to end tens of thousands of lawsuits ...

GSK's share price surged 6% yesterday in the biggest rise seen since December 2022, after the company settled 93% of cases related to the Zantac litigation. The settlement will be reflected in Q3 ...

GSK shares jumped more than 5 per cent on Thursday after the pharma giant said it will pay up to £1.7billion to settle thousands of legal cases that claimed its heartburn drug Zantac caused cancer.